--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------
07.07.2006
Intercell announced today that Merrill Lynch International, the underwriter of
its recent public offering of common shares, has exercised in full the
over-allotment option which was granted by the selling shareholders. The
over-allotment comprised of 1,142,848 existing shares of common stock which were
placed at the offer price of EUR 12.36. Following the exercise of the
over-allotment option, the gross proceeds from the combined primary and
secondary offering totaled EUR 110.6 million.
Intercell’s major shareholders following the exercise of the over-allotment
option are: Apax Partners (11.6 %), Temasek Holdings (8.1 %), Novartis (6.1 %),
TVM Capital (6.0 %) and Kapital & Wert Group (5.7 %). 1.3 % of the shares issued
are held by Intercell as treasury stock and 1.8 % are held by the management.
The current free float is 59.3 %.
Intercell has a total of 39,531,897 issued shares of common stock, which
includes 518,389 shares of treasury stock.
Not for distribution in the United States, Canada and Japan
This press release does not constitute an offer to sell or the solicitation of
an offer to purchase the shares of Intercell AG. The shares offered in
connection with the public offering in Austria have already been placed.
The information contained herein is not for publication or distribution in the
United States, Canada, Japan or Australia. This press release is not an offer of
securities for sale in the United States. The securities referred to herein have
not been and will not be registered under the U.S. Securities Act of 1933, as
amended (the Securities Act), and may not be offered or sold in the United
States absent registration under that Securities Act or an available exemption
from it. Any offering of securities to be made in the United States will be made
by means of an offering circular that may be obtained from Intercell AG and will
contain detailed information about the company and management, as well as
financial statements.
This communication expressly or implicitly contains certain forward-looking
statements concerning Intercell AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Intercell AG to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Intercell
AG is providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.
This press release is directed at and/or for distribution in the UK only to (i)
persons who have professional experience in matters relating to investments
falling within article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (ii) high net worth entities
falling within article 49(2)(a) to (d) of the Order (all such persons being
together referred to as "relevant persons"). This press release is directed
only at relevant persons. Any person who is not a relevant person should not
act or rely on this press release or any of its contents. Any investment or
investment activity to which this press release relates is available only to
relevant persons and will be engaged in only with relevant persons.
Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com
end of announcement euro adhoc 07.07.2006 06:55:44
--------------------------------------------------------------------------------
emitter: Intercell AG
Campus Vienna Biocenter 6
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
ISIN: AT0000612601
indexes:
stockmarkets: official market: Wiener Börse AG
sector: Biotechnology
language: English
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB
